Jefferies analyst Chris Howerton downgraded Landos Biopharma to Underperform from Hold with a price target of 10c, down from 20c.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LABP:
- Landos Biopharma provides update on clinical development plans
- Landos Biopharma announces $16.7M private placement financing
- Landos Biopharma Provides Comprehensive Update on Clinical Development Plans
- Landos Biopharma Announces $16.7 Million Private Placement Financing
- Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update